<DOC>
	<DOCNO>NCT00434161</DOCNO>
	<brief_summary>The purpose study evaluate efficacy effect palifermin incidence oral mucositis subject multiple myeloma receive Melphalan follow autologous peripheral blood stem cell transplantation . Amendment 01 ( April 07 ) introduce three cataract assessment carry Screening , Month 6 Month 12 response FDA EMEA follow measure .</brief_summary>
	<brief_title>A Study Palifermin Reduction Oral Mucositis Subjects With Multiple Myeloma</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , multicenter Phase IIIb study palifermin give dose chemotherapy ( total 6 dos ) dose chemotherapy ( total 3 dos ) , subject Multiple Myeloma ( MM ) receive high dose melphalan ( chemotherapy ) , 1-day schedule , follow autologous Peripheral Blood Stem Cell Transplantation ( PBSCT ) . All subject follow disease progression , second primary tumor , additional malignancy survival 10 year . Planned : 275 subject , fact , 281 subject randomize . Randomized : 115 subject palifermin pre/post-CT , 109 subject palifermin pre-CT 57 subject placebo Analyzed : 281 subject full analysis set , 277 subject safety subset . Efficacy Oral cavity assessment , patient report outcome ( PRO ) questionnaires ( Oral Mucositis Daily Questionnaire [ OMDQ ] , Functional Assessment Cancer Therapy Esophageal [ FACT-E ] , European Quality Life Utility Scale [ EQ 5D ] , Mucositis Chronic Symptoms Questionnaire [ MCSQ ] ) . Safety Physical examination ( include body temperature ) , concomitant medication , transfusion , vital sign , laboratory assessment ( hematology , chemistry ) , cataract assessment , adverse event ( AEs ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Multiple myeloma ( MM ) subject schedule receive highdose Melphalan one day schedule follow autologous peripheral blood progenitor cell ( PBSCT ) Body Mass Index ( BMI ) ≤ 35 Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 , ECOG status 3 reason status 3 exclusively due MM ( e.g . pathological fracture ) Functional hematopoietic , hepatorenal pulmonary system Subjects minimum baseline best correct visual acuity ( BCVA ) 20/40 , ( 6/12 0.5 decimal scale ) well use ETDRS chart one eye Subject minimum one eye natural , intact lens Subject LOCS III score baseline P &lt; 1.0 , C &lt; 2.0 NO &lt; 2.0 least one eye Women child bear potential must negative pregnancy test Presence history malignancy ( curatively treat basal cell squamous cell carcinoma skin , situ cervical carcinoma , surgically cured malignancy , without evidence disease &gt; 3 year Prior autologous allogeneic transplant Prior treatment palifermin , fibroblast keratinocyte growth factor Receiving dialysis History cataract surgery eye Incapable responsive mydriatic agent History ocular disease ( e.g. , macular degeneration , glaucoma , corneal disease ) would make assessment visual status difficult Subject schedule undergo cataract surgery Subject disease , opinion ophthalmologist , could adversely effect subject 's vision course study Currently active oral mucositis infection Positive HIV , hepatitis B C Subject unable unwilling follow study procedure Subject pregnant breast feeding Subject agree use adequate contraceptive precaution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Palifermin</keyword>
	<keyword>KGF</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Oncology</keyword>
	<keyword>Oral Mucositis</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Cataract</keyword>
</DOC>